These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30005109)

  • 1. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
    Quertermous J; Desai S; Harper J; Lebwohl M; Torres A; Kircik LH
    J Drugs Dermatol; 2018 Jul; 17(7):s17-s22. PubMed ID: 30005109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yes to Appropriate Compounding, No to Illegal Compounding.
    Kircik LH
    J Drugs Dermatol; 2018 Jul; 17(7):s15-s16. PubMed ID: 30005108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The U.S. Food and Drug Administration responds to the International Academy of Compounding Pharmacists' outsourcing letter.
    Int J Pharm Compd; 2014; 18(3):208. PubMed ID: 25306767
    [No Abstract]   [Full Text] [Related]  

  • 4. End-preparation assessments and tests for compounded sterile preparations.
    McElhiney LF
    Int J Pharm Compd; 2013; 17(4):307-11. PubMed ID: 24261146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak.
    Teshome BF; Reveles KR; Lee GC; Ryan L; Frei CR
    J Am Pharm Assoc (2003); 2014; 54(4):441-5. PubMed ID: 25063265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traditional vs. nontraditional pharmacy.
    Allen LV
    Int J Pharm Compd; 2013; 17(4):351. PubMed ID: 24261152
    [No Abstract]   [Full Text] [Related]  

  • 9. Sterile compounding: clinical, legal, and regulatory implications for patient safety.
    Qureshi N; Wesolowicz L; Stievater T; Lin AT
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1183-91. PubMed ID: 25443512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IACP's continuing support of compounding pharmacists: letter to the FDA concerning 503B outsourcing facilities.
    Miller DG
    Int J Pharm Compd; 2014; 18(2):117-8. PubMed ID: 24881114
    [No Abstract]   [Full Text] [Related]  

  • 12. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compounding interest: a tragedy caused by contaminated steroids turned the spotlight on compounding pharmacies.
    Hinkley KN
    State Legis; 2013 Jun; 39(6):22-3. PubMed ID: 23805443
    [No Abstract]   [Full Text] [Related]  

  • 15. U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List).
    Int J Pharm Compd; 2016; 20(6):457-458. PubMed ID: 28339383
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulating compounding pharmacies.
    Noble A
    NCSL Legisbrief; 2015 Jun; 23(23):1-2. PubMed ID: 26137607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounding pharmacies: before and after an inspection.
    Kulkarni D; Ricketts S
    Int J Pharm Compd; 2013; 17(5):358-62. PubMed ID: 24459779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could State Regulations be the Next Frontier in Preemption Jurisprudence? Drug Compounding as a Case Study.
    Brown NA; Tomar E
    Food Drug Law J; 2016; 71(2):271-99. PubMed ID: 29140058
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies.
    Kastango ES
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):38S-39S. PubMed ID: 22275322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.